Fibroblast growth factor

Basilea announces data presentations at ESMO Virtual Congress 2020

Retrieved on:

Tuesday, July 28, 2020

Branches of biology, Tyrosine kinase receptors, Basilea Pharmaceutica, Cell biology, ESMO, Fibroblast growth factor receptor, European Society for Medical Oncology, Oncology, Fibroblast growth factor, Biology

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that three abstracts featuring preclinical and clinical data on its fibroblast growth factor receptor (FGFR) kinase inhibitor derazantinib and its tumor checkpoint controller lisavanbulin are going to be presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which is taking place from 19-21 September, 2020.

Key Points:

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that three abstracts featuring preclinical and clinical data on its fibroblast growth factor receptor (FGFR) kinase inhibitor derazantinib and its tumor checkpoint controller lisavanbulin are going to be presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which is taking place from 19-21 September, 2020.
Dr. Marc Engelhardt, Chief Medical Officer, said: The preclinical derazantinib data may provide an explanation for differences in reported adverse event profiles between various FGFR kinase inhibitors.
He continued: We are also pleased that the full data from the phase 1 study with oral lisavanbulin in patients with recurrent glioblastoma will be presented at ESMO.
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

Basilea announces completion of patient enrolment into first cohort of phase 2 study FIDES-01 with derazantinib in bile duct cancer (iCCA)

Retrieved on:

Monday, July 20, 2020

Branches of biology, Medical specialties, Tyrosine kinase receptors, Hepatology, Medicine, Fibroblast growth factor receptor 2, Cholangiocarcinoma, Bile duct, Basilea Pharmaceutica, Fibroblast growth factor

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the completion of patient enrolment into the first cohort of the phase 2 registrational study, FIDES-01, assessing the activity of the FGFR kinase inhibitor derazantinib in patients with intrahepatic cholangiocarcinoma (iCCA), a form of bile duct cancer.

Key Points:

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the completion of patient enrolment into the first cohort of the phase 2 registrational study, FIDES-01, assessing the activity of the FGFR kinase inhibitor derazantinib in patients with intrahepatic cholangiocarcinoma (iCCA), a form of bile duct cancer.
This first cohort enrolled patients with iCCA expressing fusions of the fibroblast growth factor receptor 2 (FGFR2) gene and reached its target enrolment of 100 patients.
This cohort is assessing the activity of derazantinib in patients with FGFR2 gene mutations or amplifications, thus broadening the range of investigated FGFR2-driven tumors.
The first study, FIDES-01, is a registrational phase 2 study in patients with inoperable or advanced iCCA.

RIBOMIC Announces Dosing of First Subject in RBM-007 Phase 1 Clinical Trial for Achondroplasia

Retrieved on:

Wednesday, July 15, 2020

Achondroplasia has no known cure, and is designated as an intractable disease by the Ministry of Health, Labour and Welfare in Japan.

Key Points:

Achondroplasia has no known cure, and is designated as an intractable disease by the Ministry of Health, Labour and Welfare in Japan.
This disease results mainly from a genetic variant in FGFR3 (fibroblast growth factor type 3 receptor).
Achondroplasia occurs in a frequency of 1 in approximately 25,000 normal live births and is estimated to affect approximately 250,000 people worldwide.
"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

FDA Approves First Therapy for Rare Disease that Causes Low Phosphate Blood Levels, Bone Softening

Retrieved on:

Thursday, June 18, 2020

Branches of biology, Musculoskeletal system, Growth factors, Anatomy, Vitamin D, Fibroblast growth factor 23, Bones, Fibroblast growth factor, Osteomalacia, Bone, Electrolyte, KRN23

The tumors associated with TIO release a peptide hormone-like substance known as fibroblast growth factor 23 (FGF23) that lowers phosphate levels.

Key Points:

The tumors associated with TIO release a peptide hormone-like substance known as fibroblast growth factor 23 (FGF23) that lowers phosphate levels.
"Treatment for TIO focuses on identifying and removing the tumor that causes the disease.
FGF23 regulates levels of phosphate, an electrolyte that plays important roles in bone maintenance, energy production by cells and nerve function.
When there is not enough phosphate in the body, bones begin to soften and weaken, causing osteomalacia (marked softening of bones).

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China

Retrieved on:

Tuesday, March 31, 2020

Cancer, Branches of biology, Neoplasms, Occupational diseases, Asbestos, Mesothelioma, RTT, Fibroblast growth factor

LONDON, March 31, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors (FGFR), in patients with advanced malignant mesothelioma.

Key Points:

LONDON, March 31, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors (FGFR), in patients with advanced malignant mesothelioma.
The clinical study is a single-arm, multi-center, open-label study, evaluating the efficacy, safety and pharmacokinetics of HMPL-453 in historically confirmed patients with advanced malignant mesothelioma that failed at least one line of systemic therapy.
Secondary outcome measures include preliminary efficacy such as disease control rate (DCR), time to response (TTR), duration of response (DoR), progression-free survival (PFS), and overall survival (OS).
The lead investigator of the study is Shun Lu, Professor at Shanghai Chest Hospital, Jiao Tong University.

GeneCentric Therapeutics to Present New Analyses of Molecular Characterization and Prediction of Treatment Response in Patients with Muscle Invasive Bladder Cancer (MIBC)

Retrieved on:

Thursday, February 13, 2020

Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Immune system, Branches of biology, Medicine, Organ systems, Programmed cell death protein 1, Checkpoint inhibitor, PD-L1, Immune checkpoint, Fibroblast growth factor receptor, Fibroblast growth factor

GeneCentric Therapeutics today announced it will present two posters during the ASCO GU Cancers Symposium to be held in San Francisco, California, February 13-15, 2020.

Key Points:

GeneCentric Therapeutics today announced it will present two posters during the ASCO GU Cancers Symposium to be held in San Francisco, California, February 13-15, 2020.
The data are derived from GeneCentrics expertise in the identification of RNA-based Predictive Response Signatures and through collaborations with researchers at leading institutions and pharmaceutical companies.
The predictive value of fibroblast growth factor (FGFR) alterations on the treatment outcome of MIBC patients treated with immune checkpoint blockade (Anti-PD-L1/Anti-PD-1) was evaluated in the current analysis.
Details of the presentations are as follows:
GeneCentric Therapeutics, Inc., based in Research Triangle Park, N.C., is an RNA-based genomic solutions provider.

Fibroblast Growth Factor 2 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on:

Monday, December 30, 2019

Health, Pharmaceutical, Branches of biology, Growth factors, Biology, Basic fibroblast growth factor, Fibroblast growth factor, Wound healing, NUDT6, Trafermin

The "Fibroblast Growth Factor 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Fibroblast Growth Factor 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
According to the recently published report 'Fibroblast Growth Factor 2 - Pipeline Review, H2 2019'; Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) pipeline Target constitutes close to 10 molecules.
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Basic fibroblast growth factor also known as bFGF or FGF2 is a member of the fibroblast growth factor family.
This protein plays an important role in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth.

Rainier Therapeutics Announces Vofatamab FIERCE-22 Data Accepted for Presentation at ESMO 2019 Annual Congress

Retrieved on:

Monday, July 29, 2019

Vofatamab (formerly B-701) is an antibody specifically targeted against the fibroblast growth factor receptor 3 (FGFR3), a known driver of bladder and potentially other FGFR-driven cancers.

Key Points:

Vofatamab (formerly B-701) is an antibody specifically targeted against the fibroblast growth factor receptor 3 (FGFR3), a known driver of bladder and potentially other FGFR-driven cancers.
Vofatamab is the most advanced targeted antibody specific for FGFR3 known by Rainier Therapeutics to be in clinical development.
Vofatamab is currently being evaluated in two clinical trials: FIERCE-22 and FIERCE-21.
Rainier Therapeutics, Inc. is a privately held, clinical stage biotechnology company developing vofatamab, a targeted antibody for the potential treatment of metastatic bladder cancer.

Growth Factors Market is Projected to Reach ~ US$ 2.5 Bn by the end of 2029 - PMR

Retrieved on:

Wednesday, July 17, 2019

Branches of biology, Growth factors, Protein domains, Biology, Immune system, Fibroblast growth factor, Platelet-derived growth factor, Neurotrophic factors

NEW YORK, July 17, 2019 /PRNewswire/ -- According to the latest market report published by PMR on the growth factors market during 2014 2018 and forecast for 2019 2029, the global growth factors market is projected to reach ~ US$ 2.5 Bn by the end of 2029.

Key Points:

NEW YORK, July 17, 2019 /PRNewswire/ -- According to the latest market report published by PMR on the growth factors market during 2014 2018 and forecast for 2019 2029, the global growth factors market is projected to reach ~ US$ 2.5 Bn by the end of 2029.
Get PDF Brochure for Research Insights at: https://www.persistencemarketresearch.com/samples/4456
Moreover, the increasing demand for growth factors in tissue regeneration and regenerative medicines is also expected to propel the growth of the global growth factors market.
However, the high cost of some growth factors and lack of skilled professionals are among the major factors hindering the growth of the growth factors market.
Based on product type, the global growth factors market has been segmented into Interleukin (ILs), Epidermal Growth Factors (EGFs), Transforming Growth Beta Factor (TGF-beta), Fibroblast Growth Factors (FGFs), Insulin-Like Growth Factors (IGFs), Platelet-Derived Growth Factors (PDGFs), Hepatocyte Growth Factors (HGFs), Vascular Endothelial Growth Factors (VEGFs), Tumor Necrosis Factors (TNFs), and others.

Growth Factors Market is Projected to Reach ~ US$ 2.5 Bn by the end of 2029 - PMR

Retrieved on:

Wednesday, July 17, 2019

Branches of biology, Growth factors, Protein domains, Biology, Immune system, Fibroblast growth factor, Platelet-derived growth factor, Neurotrophic factors

NEW YORK, July 17, 2019 /PRNewswire/ -- According to the latest market report published by PMR on the growth factors market during 2014 2018 and forecast for 2019 2029, the global growth factors market is projected to reach ~ US$ 2.5 Bn by the end of 2029.

Key Points:

NEW YORK, July 17, 2019 /PRNewswire/ -- According to the latest market report published by PMR on the growth factors market during 2014 2018 and forecast for 2019 2029, the global growth factors market is projected to reach ~ US$ 2.5 Bn by the end of 2029.
Get PDF Brochure for Research Insights at: https://www.persistencemarketresearch.com/samples/4456
Moreover, the increasing demand for growth factors in tissue regeneration and regenerative medicines is also expected to propel the growth of the global growth factors market.
However, the high cost of some growth factors and lack of skilled professionals are among the major factors hindering the growth of the growth factors market.
Based on product type, the global growth factors market has been segmented into Interleukin (ILs), Epidermal Growth Factors (EGFs), Transforming Growth Beta Factor (TGF-beta), Fibroblast Growth Factors (FGFs), Insulin-Like Growth Factors (IGFs), Platelet-Derived Growth Factors (PDGFs), Hepatocyte Growth Factors (HGFs), Vascular Endothelial Growth Factors (VEGFs), Tumor Necrosis Factors (TNFs), and others.